Skip to main content

Table 3 Treatment compliance

From: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

  Number of cycles (%)
  DD/DI arm HDI arm
N° cycles delivered 272 701
According to protocol 72 (26) 187 (27)
Modified in dose less than 20% 64 (23) 176 (25)
Modified in dose more than 20% 136 (50) 338 (48)
\